Bioamber (NYSE:BIOA) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

BIOA has been the topic of several other reports. Cowen reiterated a “hold” rating and issued a $1.00 target price on shares of Bioamber in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Bioamber from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Bioamber in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $6.50.

Bioamber (NYSE:BIOA) traded down $0.03 during trading hours on Wednesday, reaching $0.07. 12,990,000 shares of the company’s stock traded hands, compared to its average volume of 2,860,000. The company has a quick ratio of 0.75, a current ratio of 1.08 and a debt-to-equity ratio of 0.24. The firm has a market cap of $2.17, a price-to-earnings ratio of -0.10 and a beta of 2.52. Bioamber has a 12 month low of $0.06 and a 12 month high of $3.74.

Hedge funds have recently modified their holdings of the company. Robecosam AG lifted its holdings in shares of Bioamber by 82.9% in the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 670,000 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Bioamber by 336.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 41,701 shares during the last quarter. FMR LLC lifted its holdings in shares of Bioamber by 1.9% in the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Bioamber by 9.9% in the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after acquiring an additional 27,278 shares during the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

WARNING: “Bioamber (BIOA) Rating Increased to Hold at ValuEngine” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/bioamber-bioa-rating-increased-to-hold-at-valuengine/1866649.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.